Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Parallel 37: Hepatitis C: Pre‐Approval Clinical Studies II
Fulya Günşar, İlker Turan, Galip Ersöz, Zeki Karasu, Ömer Özütemiz, Eric Lawitz, Fred Poordad, Robert H. Hyland, Lin Liu, Hadas Dvory, Phillip S. Pang, Diana M. Brainard, Julio Gutiérrez, Julio Guti- Errez, Paul Y. Kwo, Michael Bennett, Stanley Wang, Hugo E. Vargas, David Wyles, J Overcash, Peter Ruane, Benedict Maliakkal, Asma Siddique, Bal Raj Bhandari, Ran Liu, Chih-Wei Lin, Teresa I. Ng, Federico Mensa, Jens Kort, Daniela Sia, Andrew Harrington, Zhongyang Zhang, Genís Campreciós, Sara Toffanin, Agrin Moeini, M. Isabel Fiel, Ke Hao, Mónica Higuera, Oriana Miltiadous, Laia Cabellos, Helena Cornellà, Yujin Hoshida, Sander Florman, Myron Schwartz, Josep M. Llovet (2015). Parallel 37: Hepatitis C: Pre‐Approval Clinical Studies II. Hepatology, 62(S1), pp. 337A-341A, DOI: 10.1002/hep.28207.
Article285 days agoElevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients
Eric Lawitz, Kelvin W. Li, Edna Nyangau, Tyler Field, Jen‐Chieh Chuang, Andrew N. Billin, Lulu Wang, Ya Wang, Ryan S. Huss, Chuhan Chung, G. Mani Subramanian, Robert P. Myers, Marc Hellerstein (2022). Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients. , 63(9), DOI: https://doi.org/10.1016/j.jlr.2022.100250.
Article11 days agoSAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis
Eric Lawitz, Edward Gane, Peter Ruane, Robert Herring, Ziad Younes, Paul Y. Kwo, Jie Zhang, Catherine Jia, Jay Chuang, B. Mccolgan, Chuhan Chung, Mani Subramanian, Robert P. Myers, Michael S. Middleton, Kelvin W. Li, Marc Hellerstein, Mazen Noureddin, Stephen A. Harrison, Rohit Loomba (2019). SAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis. , 70(1), DOI: https://doi.org/10.1016/s0618-8278(19)31582-8.
Article11 days agoAcetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis
Eric Lawitz, Angie Coste, Fred Poordad, Naim Alkhouri, Nicole Loo, B. Mccolgan, Jacqueline M. Tarrant, Tuan Nguyen, Ling Han, Chuhan Chung, Adrian S. Ray, John G. McHutchison, G. Mani Subramanian, Robert P. Myers, Michael S. Middleton, Claude B. Sirlin, Rohit Loomba, Edna Nyangau, Mark Fitch, Kelvin W. Li, Marc Hellerstein (2018). Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis. , 16(12), DOI: https://doi.org/10.1016/j.cgh.2018.04.042.
Article11 days agoSu1522 - Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (ASK-1) Inhibitor (Selonsertib) in Combination with an Acetyl-Coa Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor (FXR) Agonist (GS-9674) in NASH
Eric Lawitz, Robert Herring, Ziad Younes, Edward Gane, Peter Ruane, Raúl Antonio Aguilar Vera, Catherine Jia, Ren Xu, B. Mccolgan, Macky Natha, C. Stephen Djedjos, Mani Subramanian, John G. McHutchison, Robert P. Myers, Michael S. Middleton, Kelvin W. Li, Marc Hellerstein, Paul Y. Kwo, Mazen Noureddin, Stephen A. Harrison (2018). Su1522 - Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (ASK-1) Inhibitor (Selonsertib) in Combination with an Acetyl-Coa Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor (FXR) Agonist (GS-9674) in NASH. , 154(6), DOI: https://doi.org/10.1016/s0016-5085(18)33863-0.
Article11 days ago